[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551069":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":31,"centralContacts":37,"locations":44,"responsibleParty":65,"collaborators":30,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":30,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":46,"whyStopped":30,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Psilocybin Administration Session 1","EXPERIMENTAL","Participants will receive one dose of psilocybin ranging from low (\"microdose\") to high and either pimavanserin or a placebo capsule in a medically monitored setting with preparation sessions before and integration sessions after.",[13,14],"Drug: Psilocybin","Drug: Pimavanserin",{"label":16,"type":10,"description":11,"interventionNames":17},"Psilocybin Administration Session 2",[13,14],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Psilocybin","Single dose of psilocybin ranging from low (\"microdose\") to high delivered orally in two separate drug administration sessions with psychological support and monitoring.",[9,16],[25],"4-phosphoryloxy- N,N-dimethyltryptamine",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Pimavanserin","Participants will receive either pimavanserin or placebo during their drug administration sessions.",[9,16],null,[32,35],{"name":33,"affiliation":5,"role":34},"Joshua Woolley, MD,PhD","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":5,"role":34},"Ellen Bradley, MD",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":30,"email":42},"Brigette Sosa","CONTACT","(415) 935-3489","pdp2@ucsf.edu",{"name":36,"role":40,"phone":30,"phoneExt":30,"email":30},[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","San Francisco","California","94143","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-122.41942,37.77493,{"lat":56,"lon":55},[59,60,62,63],{"name":39,"role":40,"phone":41,"phoneExt":30,"email":42},{"name":61,"role":40,"phone":30,"phoneExt":30,"email":42},"Kimberly Sakai",{"name":33,"role":34,"phone":30,"phoneExt":30,"email":30},{"name":36,"role":64,"phone":30,"phoneExt":30,"email":30},"SUB_INVESTIGATOR",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Joshua Woolley, MD, PhD","Principal Investigator","100551069","phase-2-psilocybin-therapy-for-depression-in-parkinsons-disease-100551069",false,"NCT06455293","Psilocybin Therapy for Depression in Parkinson's Disease","The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","PDP2","Inclusion Criteria:\n\n* Age 40 to 80\n* Comfortable speaking and writing in English\n* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an \"on\" phase (time when medication\u002FDBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)\n* Currently experiencing depressive symptoms\n* Able to attend all in-person visits at UCSF as well as virtual visits\n* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating\n\nExclusion Criteria:\n\n* Psychotic symptoms involving loss of insight\n* Significant cognitive impairment\n* Regular use of medications that may have problematic interactions with psilocybin\n* A health condition that makes this study unsafe or unfeasible, determined by study physicians","ALL","40 Years","80 Years",{"count":81,"type":82},60,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.",[88,89],"Parkinson Disease","Depression",[88,89,21,91,92],"Psilocybin therapy","Movement disorder","2026-08-04",{"date":95,"type":96},"2026-08-07","ACTUAL",{"date":98,"type":96},"2024-08-19",{"date":100,"type":82},"2028-06",{"name":67,"class":6},1]